AUY954, a selective S1P(1) modulator, prevents experimental autoimmune neuritis

J Neuroimmunol. 2009 Nov 30;216(1-2):59-65. doi: 10.1016/j.jneuroim.2009.09.010. Epub 2009 Oct 4.

Abstract

Experimental autoimmune neuritis (EAN) is a T cell-mediated autoimmune inflammatory demyelinating disease of the peripheral nervous system and an animal model of human inflammatory demyelinating polyradiculoneuropathy. AUY954, which targets selectively the sphingosine-1-phosphate receptor 1 (S1P(1)), is known to sequester lymphocytes into secondary lymphoid tissues. In EAN rats, AUY954 greatly prevented paraparesis if administrated from the day of immunization. T cell, B cell, and macrophage infiltration, inflammatory demyelination, and local expression of interleukine-17 and matrix metalloproteinase-9 in sciatic nerves of EAN rats were significantly decreased by AUY954 treatment. Therefore, S1P(1) modulation might be a potential treatment option for inflammatory neuropathies.

MeSH terms

  • Animals
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / immunology
  • Chemotaxis, Leukocyte / drug effects
  • Chemotaxis, Leukocyte / immunology
  • Disease Models, Animal
  • Guillain-Barre Syndrome / drug therapy*
  • Guillain-Barre Syndrome / immunology
  • Guillain-Barre Syndrome / metabolism
  • Immunologic Factors / pharmacology
  • Immunologic Factors / therapeutic use
  • Interleukin-17 / metabolism
  • Macrophages / drug effects
  • Macrophages / immunology
  • Male
  • Matrix Metalloproteinase 9 / metabolism
  • Neuritis, Autoimmune, Experimental / drug therapy*
  • Neuritis, Autoimmune, Experimental / immunology
  • Neuritis, Autoimmune, Experimental / metabolism
  • Paraparesis / drug therapy
  • Paraparesis / immunology
  • Paraparesis / prevention & control
  • Rats
  • Rats, Inbred Lew
  • Receptors, Lysosphingolipid / drug effects*
  • Receptors, Lysosphingolipid / metabolism
  • Sciatic Nerve / drug effects
  • Sciatic Nerve / immunology
  • Sciatic Nerve / metabolism
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology
  • Thiophenes / pharmacology*
  • Thiophenes / therapeutic use
  • Treatment Outcome
  • beta-Alanine / analogs & derivatives*
  • beta-Alanine / pharmacology
  • beta-Alanine / therapeutic use

Substances

  • AUY 954
  • Immunologic Factors
  • Interleukin-17
  • Receptors, Lysosphingolipid
  • Thiophenes
  • beta-Alanine
  • Matrix Metalloproteinase 9